Hepatitis B Virus_Surface Gene Mutations and Their Clinical Implications

Hamadalnil, Yassir; Bakheit, S. M.

doi:10.18502/sjms.v12i2.920

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These mutations played a significant role in the virus immune escape, and these variations have largely been justified by factors associated with host immunity, such as HBV-specific T-and/or B-cell production, and antigen presentation failure. Additionally, viral determinants, such as the HBV genotypes and their evolving variants, have played a significant role in contributing to these variations [39,40]. A study reported that surface antigen causes dysfunction of myeloid dendritic cells, which serve as a possible immune escape mechanism in HBV [39].…”

Section: Discussionmentioning

confidence: 99%

Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients

Gohar,

Rehman,

Ullah

et al. 2023

Microorganisms

View full text Add to dashboard Cite

Several nucleotide analogues have been approved for use in treating hepatitis B virus (HBV) infection. Long-term exposure to therapy leads to the emergence of mutations within the HBV DNA polymerase gene, resulting in drug resistance, a major factor contributing to therapy failure. Chronic HBV patients from the Khyber Pakhtunkhwa province, Pakistan, who had completed 6 months of therapy participated in this study. Samples were collected from 60 patients. In this study, the entire reverse transcriptase domain of the HBV polymerase gene was amplified using nested polymerase chain reaction and sequenced. Drug-resistant mutations were detected in nine (22.5%) patients. All of these patients had lamivudine-resistant mutations (rtM204V + L180M), while seven individuals (17.5%) had both lamivudine- plus entecavir-resistant mutations (L180M + M204V + S202G). N236T, a mutation that gives rise to tenofovir and adefovir resistance, was observed in two (5%) patients. T184A, a partial drug-resistant mutation to entecavir, was found in five (12.5%) patients. Furthermore, other genotypic variants (100%) and vaccine escape mutations (5%) were additionally observed. Moreover, pN459Y (35%), pN131D (20%), pL231S (20%), pP130Q (17.5%), pS189Q (12.5%), pP161S (5%), pH160P (2.5%), pT322S (2.5%), and pA223S (2.5%) mutations in the polymerase gene, as well as sA166V (17.5%), sQ181K (12.5%), sV184R (7.5%), sA17E (5%), sP153S/K (5%), sW156C (5%), sC76Y (2.5%), and S132F (2.5%) mutations in the small surface gene, were identified for the first time in this study. Phylogenetic analysis showed that genotype D was predominant amongst the HBV carriers. Subtype D1 was found in most patients, while two patients were subtype D9. These novel findings may contribute to the body of knowledge and have clinical significance for treating and curing HBV infections in Pakistan.

show abstract

Section: Discussionmentioning

confidence: 99%

Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients

Gohar,

Rehman,

Ullah

et al. 2023

Microorganisms

View full text Add to dashboard Cite

show abstract

“…HBV vaccine is a recombinant DNA vaccine that contains HBsAg genetically engineered from the yeast Saccharomyces cerevisiae. It provides a seroprotection rate of 85-100% that was seen one month after the last dose of vaccine and it confers immunity for at least 10 years [5]. Hepatitis B vaccine is recommended for unvaccinated adults who are at risk for HBV infection like people whose sex partners have hepatitis B, sexually active persons who are not in a long-term monogamous relationship, persons seeking evaluation or treatment for a sexually transmitted disease, men who have sex with men, people who share needles, syringes, or other drug-injection equipment, household contacts of HBV-infected persons, health personnel and public safety workers at risk for exposure to blood or body fluids, residents and staff of facilities for developmentally disabled persons, persons in correctional facilities, victims of sexual assault or abuse, travelers to regions with increased rates of hepatitis B, people with chronic liver disease, patients on hemodialysis, HIV infection, or diabetes, and anyone who wants to be protected from HBV.…”

Section: Introductionmentioning

confidence: 99%

A Cross-sectional Study on Hepatitis B Immune Status among Vaccinated Healthcare Workers in Khartoum, Sudan

Mahgoub

Hamadalnil²,

Mohammed³

et al. 2020

Sudan JMS

View full text Add to dashboard Cite

Background: Hepatitis B virus (HBV) infection can lead to chronic hepatitis, liver cirrhosis, and Hepatocellular Carcinoma (HCC). Vaccination against the virus plays an important role in its prevention. Health personnel at risk of infection are recommended to receive the vaccine and to check their immune status thereafterObjective: To determine Hepatitis B Immune status among vaccinated health personnel in Khartoum state, Sudan.A total of 106 health personnel from different hospitals and doctors’mess in Khartoum and from different jobs were surveyed and their HBV surface antibodies levels were determined by HBsAb (Quantitative) ELISA Kits.Methods: Of the 106 participants in this study, the majority were females 72.6%. The mean age of those involved was 27.69 years, and nurses made for more than 50% of those surveyed. About 56.6% (60) of the health personnel involved took three or more doses of HBV vaccine while the rest received one or two doses. The results of the participants who received three or more doses of the vaccine represented immunity by 70%. In general, about 47.2% (50) of the participants in this study did show excellent immune response (> 100 mIU/mL) and 18.9% (20) had weak protective levels (between 10 and 100 mIU/mL)So, we concluded that HBV post-vaccination immunity status of health personnel in Khartoum state is lower than post-vaccination HBV immunity in other parts of the world. There is an urgent need for a national protocol of HBV vaccination to improve the immunization status of health personnel with a regular checkup of HBV immunity and easy access to a good-quality vaccine. Keywords: hepatitis B vaccines; healthcare workers; immune response

show abstract

In silico molecular study of hepatitis B virus X protein as a therapeutic target

Hamadalnil

Altayb

2023

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

Hepatitis B Virus_Surface Gene Mutations and Their Clinical Implications

Abstract: Hepatitis B infection is a major public health problem caused by hepatitis B virus

Cited by 3 publications

References 28 publications

Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients

Phylogenetic Analysis and Emerging Drug Resistance against Different Nucleoside Analogues in Hepatitis B Virus Positive Patients

A Cross-sectional Study on Hepatitis B Immune Status among Vaccinated Healthcare Workers in Khartoum, Sudan

In silico molecular study of hepatitis B virus X protein as a therapeutic target

Contact Info

Product

Resources

About